Ege University Hospital Implants Turkey's 1st Total Artificial Heart
Total Artificial Heart Only Suitable Device for 47-Year-Old Patient with Less Than 2 Weeks to Live
TUCSON, Ariz. – Oct. 19, 2010 – On Sept. 30, Ege University Hospital in Izmir performed Turkey's first implant of the SynCardia temporary Total Artificial Heart. The surgery was led by Prof. Dr. Mustafa Ozbaran, head of the Transplant and Assist Device Program, and proctored by experienced Total Artificial Heart surgeon Dr. Latif Arusoglu.
"We have extensive experience with BiVADs, but for such a sick patient, the Total Artificial Heart was the only suitable device," said Prof. Dr. Ozbaran. "The Total Artificial Heart provides a high volume of blood flow to help recover the vital organs. There is no need for inotropes and you do not have to worry about arrhythmia."
The 47-year-old patient, who had his mitral and atrial heart valves replaced 21 years ago, was suffering from dilated cardiomyopathy. He has been waiting for a heart transplant for two years and was moved up to emergency status two and half months ago. Prior to implant, the patient had spent three weeks in the ICU and was inotrope dependent and suffering from severe arrhythmia. Doctors expected the patient's survival was less than 15 days without the Total Artificial Heart.
Ege University is one of the biggest and oldest universities in Turkey. The heart transplant program, started in 1998, has become the most active program in the country. Each year, Ege University performs approximately 1,100 open heart surgeries. In Turkey, the average wait time for a donor heart transplant is 18 to 24 months. Ege University is the first transplant hospital in Turkey and the 33rd in the world to become a SynCardia Certified Center.
SynCardia Systems, Inc. in Tucson, Arizona is the privately-held owner and manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart.
Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.
More than 1,350 implants of the SynCardia Total Artificial Heart accounts for over 400 patient years of life on the device. Since January 2011 more than 400 SynCardia Hearts have been implanted.
SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to leave the hospital to live at home and in their communities. The wearable Freedom driver has been used by over 190 patients, accounting for over 110 years of support.